Targeting of keloid with TRAIL and TRAIL-R2/DR5

Keloid is a common and frequently-occurring disease in plastic surgery, and its ugly appearance and itching symptoms bring mental and life pain to patients. However, the clinical treatment of keloid, such as drug injection treatment, surgical resection, cryotherapy, laser treatment and other therapeutic effects are poor. Since the discovery of tumor necrosis factor related apoptosis inducing ligand (TRAIL) in 1995, its selective apoptosis on tumor cells makes it have a great prospect in the targeted treatment of tumor. In recent years, it has been found that the formation of keloid is related to the imbalance of apoptosis of fibroblasts in scar and the binding of TRAI to its receptor mediates the apoptosis of fibroblasts. Therefore, the use of TRAIL and TRAIL-R2/death receptor 5 (DR5) in the treatment of keloid has become a hot research topic. In this paper, the present situation, mechanism and development prospect of TRAIL and TRAIL-R2/DR5 targeted treatment of keloid were reviewed, which provided a reference for promoting the development of keloid treatment.

Automated summary

Keloid is a common disease in plastic surgery, with poor treatment effects using methods such as drug injection, surgical resection, cryotherapy, and laser treatment. The discovery of TRAIL in 1995 has led to its potential use in targeting tumors, and recent research has shown its potential in treating keloids by inducing fibroblast apoptosis through TRAI binding to its receptor.